

Supporting Information

Supplementary methods and results

This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors.

Appendix to: Caughey GE, Air T, Rahja M, Inacio MC. The oral health care needs of people living in residential aged care, Australia, 2016–20: a retrospective cross-sectional study. *Med J Aust* 2025; doi: 10.5694/mja2.52625.

Table 1. Definitions and codes health service (Medicare Benefits Schedule), medications (Pharmaceutical Benefits Scheme, Dental Schedule), and hospitalisations

| Description | Codes | | | |
|--|---|--|--|--|
| Health services (Medicare Benefits Schedule [MBS]) | MBS Item Code | | | |
| Professional attendance (other than a second or subsequent attendance in a single course of treatment) by an approved dental practitioner, at consulting rooms, hospital or residential aged care facility where the patient is referred | 51700 | | | |
| Professional attendance by an approved dental practitioner, each attendance subsequent to the first in a single course of treatment at consulting rooms, hospital or residential aged care facility where the patient is referred | 51793 | | | |
| Medications prescribed by dental practitioners (Pharmaceutical Benefits Scheme [PBS] Dental Schedule) | PBS Item Codes | | | |
| Antibacterial medications for systemic use | | | | |
| Amoxicillin | 3301R, 3393N, 3300Q, 5225B, 3310F, 3302T, 13184X | | | |
| Amoxicillin and clavulanic acid | 5011R, 13190F, 5009P, 5008N, 5006L | | | |
| Benzathine benzylpenicillin | 11735P, 5027N | | | |
| Benzylpenicillin | 3399X, 3398W | | | |
| Cefaclor | 5046N, 5047P, 5045M | | | |
| Cefalexin | 3317N, 3318P, 3319Q, 13278W, 3320R | | | |
| Cefotaxime | 1768C | | | |
| Cefuroxime | 11191B, 11228Y, 5052X | | | |
| Clindamycin | 5057E | | | |
| Dicloxacillin | 5096F, 5097G | | | |
| Doxycycline | 3321T, 5082L, 3322W | | | |
| Erythromycin | 3325B, 3334L, 3337P | | | |
| Flucloxacillin | 5257Q, 5258R, 5090X, 5091Y, 5095E | | | |
| Lincomycin | 11366F, 5144R | | | |
| Metronidazole | 5157K, 3339R, 5155H, 3341W | | | |
| Phenoxymethylpenicillin | 3363B, 3364C, 5012T, 5024K, 5029Q, 13291M, 3360W, 3361X | | | |
| Procaine benzylpenicillin | 3371K | | | |
| Roxithromycin | 5259T, 5250W, 5261X | | | |
| Trimethoprim + sulfamethoxazole | 3391L, 3390K | | | |
| Vancomycin | 5083M, 3323X | | | |
| Anti-inflammatory and antirheumatic medications | | | | |
| Diclofenac | 5079H, 5076E, 5077F | | | |
| Ibuprofen | 5123P, 5124Q | | | |
| Indometacin | 5126T, 5128X | | | |
| Ketoprofen | 5136H | | | |
| Naproxen | 5179N, 5176K, 5178M, 5186Y | | | |
| Piroxicam | 5210R, 5204X, 5202T, 5203W | | | |
| Analgesic medications | | | | |
| Codeine | 12054K, 5063L | | | |
| Hydromorphone | 12559B, 12045Y, 5115F, 12032G, 5116G, 12010D, 5117H | | | |
| Morphine | 10863R, 10858L, 12067D, 5163R, 5168B, 5169C, 5170D, 5239R, 5237P, 5238Q | | | |
| Oxycodone | 12311Y, 13234M, 5194J, 12074L, 5197M, 5191F, 5190E, 5195K | | | |
| Paracetamol + codeine | 12066C, 3316M | | | |

| Description | Codes | | | |
|---|-----------------------------|--|--|--|
| Tramadol | 12024W, 5232J, 5231H, 5150C | | | |
| Codeine | 12054K, 5063L | | | |
| Hospitalisations (International Classification of Diseases-10 Australian modification [ICD-10AM]) | ICD-10AM Codes | | | |
| Potentially preventable dental hospitalisations | | | | |
| Dental caries | K02* | | | |
| Other diseases of hard tissues of teeth | K03* | | | |
| Diseases of pulp and periapical tissues | K04* | | | |
| Gingivitis and periodontal diseases | K05* | | | |
| Other disorders of gingiva and edentulous alveolar ridge | K06 * | | | |
| Other disorders of teeth and supporting structures | K08* | | | |
| Other cysts of oral region, not elsewhere classified | K09.8 | | | |
| Cyst of oral region, unspecified | K09.9 | | | |
| Stomatitis and related lesions | K12* | | | |
| Other diseases of lip and oral mucosa | K13* | | | |
| Diseases of tongue | K14* | | | |
| Potentially preventable dental emergency department presentations | | | | |
| Dental caries | K02* | | | |
| Other diseases of hard tissues of teeth | K03* | | | |
| Diseases of pulp and periapical tissues | K04* | | | |
| Gingivitis and periodontal diseases | K05* | | | |
| Other disorders of gingiva and edentulous alveolar ridge | K06 * | | | |
| Other disorders of teeth and supporting structures | K08* | | | |
| Other cysts of oral region, not elsewhere classified | K09.8 | | | |
| Cyst of oral region, unspecified | K09.9 | | | |
| Stomatitis and related lesions | K12* | | | |
| Other diseases of lip and oral mucosa | K13* | | | |
| Diseases of tongue | K14* | | | |
| Dental procedures requiring anaesthesia, Australian Classification of Health Interventions (ACHI) | ACHI codes | | | |
| Nonsurgical removal of tooth | 457* | | | |
| Surgical removal of tooth | 458* | | | |
| Pulp treatment | 462* | | | |
| Periradicular surgery | 463* | | | |
| Metallic restoration | 465* | | | |
| Tooth-coloured restoration | 466* | | | |
| Other restorative dental service | 469* | | | |
| Crown | 470* | | | |
| Bridge | 471* | | | |
| Other dental service on crown and bridge | 472* | | | |
| Tooth root resection, per root | 97241-00 | | | |
| Replantation and splinting of tooth | 97387-00 | | | |
| Transplantation of tooth or tooth bud | 97388-00 | | | |
| Exploration or negotiation of calcified root canal, per canal | 97445-00 | | | |
| Obturation of resorption defect or perforation | 97457-00 | | | |
| Interim therapeutic root filling | 97458-00 | | | |
| Provision of resin splint, indirect | 97772-00 | | | |
| Provision of metal splint, indirect | 97773-00 | | | |

| Description | Codes | | |
|---|----------------|--|--|
| Metallic inlay for denture tooth | 97778-00 | | |
| Australian refined diagnosis-related groups (AR-DRGs) D40 dental extractions and restorations (principal diagnosis (AD40PDX1) | ICD-10AM codes | | |
| Nonsurgical removal of tooth | B00.2 | | |
| Surgical removal of tooth | B37.0 | | |
| Pulp treatment | D10.0 | | |
| Periradicular surgery | D10.1 | | |
| Metallic restoration | D10.2 | | |
| Tooth-coloured restoration | D10.3 | | |
| Other restorative dental service | D16.5 | | |
| Crown | E10.63 | | |
| Bridge | E11.63 | | |
| Other dental service on crown and bridge | E13.63 | | |
| Tooth root resection, per root | E14.63 | | |
| Disorders of tooth development and eruption | K00* | | |
| Embedded and impacted teeth | K01* | | |
| Dental caries | K02* | | |
| Other diseases of hard tissues of teeth | K03* | | |
| Diseases of pulp and periapical tissues | K04* | | |
| Gingivitis and periodontal diseases | K05* | | |
| Gingival recession | K06.0 | | |
| Gingival enlargement | K06.1 | | |
| Gingival and edentulous alveolar ridge lesions associated with trauma | K06.2 | | |
| Other specified disorders of gingiva and edentulous alveolar ridge | K06.8 | | |
| Disorder of gingiva and edentulous alveolar ridge, unspecified | K06.9 | | |
| Dentofacial anomalies | K07* | | |
| Exfoliation of teeth due to systemic causes | K08.0 | | |
| Loss of teeth due to accident, extraction or local periodontal disease | K08.1 | | |
| Atrophy of edentulous alveolar ridge | K08.2 | | |
| Retained dental root | K08.3 | | |
| Pathological fracture of tooth | K08.81 | | |
| Other specified disorders of teeth and supporting structures | K08.88 | | |
| Disorder of teeth and supporting structures, unspecified | K08.9 | | |
| Cysts of oral region, not elsewhere classified | K09* | | |
| Other diseases of jaw | K10* | | |
| Stomatitis and related lesions | K12* | | |
| Other diseases of lip and oral mucosa | K13* | | |
| Diseases of tongue | K14* | | |
| Macrostomia | Q18.4 | | |
| Microstomia | Q18.5 | | |
| Macrocheilia | Q18.6 | | |
| Microcheilia | Q18.7 | | |
| Cleft hard palate | Q35.1* | | |
| Cleft soft palate | Q35.3* | | |
| Cleft uvula | Q35.7 | | |
| Cleft palate, unspecified | Q35.9 | | |
| - ,,p | | | |

| Description | Codes | | | |
|--|----------------|--|--|--|
| Congenital malformations of lips, not elsewhere classified | Q38.0* | | | |
| Ankyloglossia | Q38.1* | | | |
| Macroglossia | Q38.2* | | | |
| Other congenital malformations of tongue | Q38.3* | | | |
| Congenital malformations of salivary glands and ducts | Q38.4* | | | |
| Congenital malformations of palate, not elsewhere classified | Q38.5* | | | |
| Other congenital malformations of mouth | Q38.6* | | | |
| Open wound of maxillary region | S01.42 | | | |
| Open wound of mandibular region | S01.43 | | | |
| Open wound of mouth, part unspecified | S01.50 | | | |
| Open wound of lip | S01.51 | | | |
| Open wound of buccal mucosa | S01.52 | | | |
| Open wound of gum (alveolar process) | S01.53 | | | |
| Open wound of tongue and floor of mouth | S01.54 | | | |
| Dislocation of tooth | S03.2 | | | |
| Sprain and strain of jaw | \$03.4 | | | |
| Foreign body in mouth | T18.0 | | | |
| AR-DRG D40 dental extractions and restorations | ACHI codes | | | |
| intervention procedure (AP40INT1) | | | | |
| Tooth root resection, per root | 97241-00 | | | |
| Surgical periodontal procedure, not elsewhere classified, per tooth or implant | 97245-00 | | | |
| Nonsurgical removal of tooth | 457* | | | |
| Surgical removal of tooth | 458* | | | |
| Replantation and splinting of tooth | 97387-00 | | | |
| Metallic restoration | 465* | | | |
| Tooth-coloured restoration | 466* | | | |
| Other restorative dental service | 469* | | | |
| Crown | 470* | | | |
| Bridge | 471* | | | |
| Other dental service on crown and bridge | 472* | | | |
| Fitting of implant abutment, per abutment | 97661-00 | | | |
| Full crown attached to osseointegrated implant, non-metallic, indirect | 97671-00 | | | |
| Full crown attached to osseointegrated implant, veneer, indirect | 97672-00 | | | |
| Full crown attached to osseointegrated implant, metallic, indirect | 97673-00 | | | |
| Provision of resin splint, indirect | 97772-00 | | | |
| Provision of metal splint, indirect | 97773-00 | | | |
| Metallic inlay for denture tooth | 97778-00 | | | |
| AR-DRG D67 oral and dental disorders (AD67PDX1) | ICD-10AM codes | | | |
| Nonsurgical removal of tooth | B00.2 | | | |
| Surgical removal of tooth | B37.0 | | | |
| Pulp treatment | D10.0 | | | |
| Periradicular surgery | D10.1 | | | |
| Metallic restoration | D10.2 | | | |
| Tooth-coloured restoration | D10.3 | | | |
| Other restorative dental service | D16.5 | | | |
| Crown | E10.63 | | | |
| Bridge | E11.63 | | | |
| | | | | |

| Description | Codes | | |
|--|--------|--|--|
| Other dental service on crown and bridge | E13.63 | | |
| Tooth root resection, per root | E14.63 | | |
| Disorders of tooth development and eruption | K00* | | |
| Embedded and impacted teeth | K01* | | |
| Dental caries | K02* | | |
| Other diseases of hard tissues of teeth | K03* | | |
| Diseases of pulp and periapical tissues | K04* | | |
| Gingivitis and periodontal diseases | K05* | | |
| Gingival recession | K06.0 | | |
| Gingival enlargement | K06.1 | | |
| Gingival and edentulous alveolar ridge lesions associated with trauma | K06.2 | | |
| Other specified disorders of gingiva and edentulous alveolar ridge | K06.8 | | |
| Disorder of gingiva and edentulous alveolar ridge, unspecified | K06.9 | | |
| Dentofacial anomalies | K07* | | |
| Exfoliation of teeth due to systemic causes | K08.0 | | |
| Loss of teeth due to accident, extraction or local periodontal disease | K08.1 | | |
| Atrophy of edentulous alveolar ridge | K08.2 | | |
| Retained dental root | K08.3 | | |
| Pathological fracture of tooth | K08.81 | | |
| Other specified disorders of teeth and supporting structures | K08.88 | | |
| Disorder of teeth and supporting structures, unspecified | K08.9 | | |
| Cysts of oral region, not elsewhere classified | K09* | | |
| Other diseases of jaw | K10* | | |
| Stomatitis and related lesions | K12* | | |
| Other diseases of lip and oral mucosa | K13* | | |
| Diseases of tongue | K14* | | |
| Macrostomia | Q18.4 | | |
| Microstomia | Q18.5 | | |
| Macrocheilia | Q18.6 | | |
| Microcheilia | Q18.7 | | |
| Cleft hard palate | Q35.1* | | |
| Cleft soft palate | Q35.3* | | |
| Cleft uvula | Q35.7 | | |
| Cleft palate, unspecified | Q35.9 | | |
| Cleft lip, bilateral | Q36.0 | | |
| Cleft lip, median | Q36.1 | | |
| Cleft lip, unilateral | Q36.9 | | |
| Congenital malformations of lips, not elsewhere classified | Q38.0* | | |
| Ankyloglossia | Q38.1* | | |
| Macroglossia | Q38.2* | | |
| Other congenital malformations of tongue | Q38.3* | | |
| Congenital malformations of salivary glands and ducts | Q38.4* | | |
| Congenital malformations of palate, not elsewhere classified | Q38.5* | | |
| Other congenital malformations of mouth | Q38.6* | | |
| Open wound of maxillary region | S01.42 | | |
| Open wound of mandibular region | S01.43 | | |

| Description | Codes |
|---|---------|
| Open wound of mouth, part unspecified | S01.50 |
| Open wound of lip | S01.51 |
| Open wound of buccal mucosa | S01.52 |
| Open wound of gum (alveolar process) | S01.53 |
| Open wound of tongue and floor of mouth | S01.54a |
| Dislocation of tooth | S03.2 |
| Sprain and strain of jaw | S03.4 |
| Foreign body in mouth | T18.0 |

ACHI, Australian Classification of Health Interventions; AR-DRG, Australian refined diagnosis-related groups; ED, emergency department; ICD-10AM, International Classification of Diseases-10 Australian modification; MBS, Medicare Benefits Schedule; PBS, Pharmaceutical Benefits Scheme.

^{*} Includes all ICD-10-AM, ACHI codes available under this block.

Table 2. Crude cumulative incidence of oral health and dental-related health service, medications, and hospital use by aged care residents included in the national historical cohort of the Registry of Senior Australians (ROSA), 1 July 2016 – 30 June 2020, overall and by study year

| Characteristic | 2016–17 to 2019–20 | 2016–17 | 2017–18 | 2018–19 | 2019–20 |
|---|-----------------------|-----------------------|-----------------------|------------------------|------------------------|
| All aged care residents | 360,305 | 198,734 | 202,878 | 206,001 | 210,590 |
| Medicare Benefits Scheme- subsidised dental practitioner health service | | | | | |
| Dental practitioner health services | 665 | 182 | 182 | 192 | 142 |
| Cumulative incidence (95% CI) | 0.18% (0.17–0.20%) | 0.09% (0.08–0.11%) | 0.09% (0.08–0.10%) | 0.09% (0.08–0.11%) | 0.07% (0.06–0.08%) |
| Pharmaceutical Benefits Scheme Dental Schedule medications | | | | | |
| Antibacterial medications (systemic) | 5988 | 1691 | 1686 | 1739 | 1428 |
| Cumulative incidence (95% CI) | 1.66% (1.62–1.70%) | 0.85% (0.81–0.89%) | 0.83% (0.79–0.87%) | 0.84% (0.81–0.88%) | 0.68% (0.64–0.71%) |
| Anti-inflammatory and anti- rheumatic medications | 43 | 13 | 13 | 9 | 9 |
| Cumulative incidence (95% CI) | 0.01% (0.01–0.02%) | 0.01% (0.00–0.01%) | 0.01% (0.00–0.01%) | 0.004% (0.00–0.01%) | 0.004% (0.00-0.01%) |
| Analgesic medications | 574 | 143 | 160 | 151 | 137 |
| Cumulative incidence (95% CI) | 0.16% (0.15–0.17%) | 0.07 (0.06–0.08%) | 0.08% (0.07–0.09%) | 0.07% (0.06–0.09%) | 0.07% (0.05–0.08%) |
| New South Wales, Victoria, South Australia aged care residents | 248 684 | 138 694 | 141 144 | 142 591 | 144 695 |
| Oral/dental health-related hospitalisations | | | | | |
| Any dental hospitalisation (primary or secondary diagnosis) | 4954 | 1251 | 1289 | 1328 | 1261 |
| Cumulative incidence (95% CI) | 1.99% (1.94–2.05%) | 0.90% (0.85–0.95%) | 0.91% (0.86–0.96%) | 0.93% (0.88–0.98%) | 0.87% (0.82–0.92%) |
| Potentially preventable dental hospitalisation (primary or secondary diagnosis) | 1167 | 304 | 287 | 313 | 282 |
| Cumulative incidence (95% CI) | 0.47% (0.44–0.50%) | 0.22% (0.20–0.24%) | 0.20% (0.18–0.23%) | 0.22% (0.20–0.25%) | 0.19% (0.17–0.22%) |
| Potentially preventable dental hospitalisation (primary diagnosis only) | 380 | 101 | 88 | 116 | 82 |
| Cumulative incidence (95% CI) | 0.15% (0.14–0.17%) | 0.07% (0.06–0.09%) | 0.06% (0.05–0.08%) | 0.08% (0.07–0.10%) | 0.06% (0.05–0.07%) |
| Potentially preventable dental emergency department presentations | 353 | 72 | 88 | 105 | 90 |
| Cumulative incidence (95% CI) | 0.14% (0.13–0.16%) | 0.05% (0.04–0.07%) | 0.06% (0.05–0.08%) | 0.07% (0.06–0.09%) | 0.06% (0.05–0.08%) |
| Dental extractions and restoration | 191 | 47 | 47 | 57 | 43 |
| Cumulative incidence (95% CI) | 0.08% (0.07–0.09%) | 0.03% (0.03–0.05%) | 0.03% (0.02-0.04%) | 0.04% (0.03–0.05%) | 0.03% (0.02-0.04%) |
| Oral and dental disorders | 795 | 202 | 189 | 235 | 186 |
| Cumulative incidence (95% CI) | 0.32% (0.30–0.34%) | 0.15% (0.13–0.17%) | 0.13% (0.12–0.15%) | 0.16% (0.15–0.19%) | 0.13% (0.11–0.15%) |

CI = confidence interval.

Table 3. Age- and sex-standardised rates of oral and dental hospitalisations per 1000 aged care residents, overall and by study year (New South Wales, Victoria, South Australia only)

| Characteristic | Total | 2016-17 | 2017-18 | 2018-19 | 2019-20 |
|--|-------------|-------------|-------------|-------------|-------------|
| Number of residents | 248,684 | 138,694 | 141,144 | 142,591 | 144,695 |
| Oral/dental-related hospitalisations | | | | | |
| Any dental/oral related hospitalisation (primary and secondary diagnosis) | 4954 | 1251 | 1289 | 1328 | 1261 |
| Rate per 1000 residents (95% CI) | 19.9 | 9.02 | 9.13 | 9.32 | 8.72 |
| | (19.4-20.5) | (8.26-9.50) | (8.63-9.63) | (8.82-9.82) | (8.24-9.21) |
| Potentially preventable dental hospitalisation (primary and secondary diagnosis) | 1167 | 304 | 287 | 313 | 282 |
| Rate per 1000 residents (95% CI) | 4.69 | 2.19 | 2.03 | 2.20 | 1.95 |
| | (4.43-4.97) | (1.94-2.43) | (1.80-2.27) | (1.96-2.45) | (1.73-2.18) |
| Potentially preventable dental hospitalisation (primary diagnosis only) | 380 | 101 | 88 | 116 | 82 |
| Rate per 1000 residents (95% CI) | 1.53 | 0.73 | 0.62 | 0.82 | 0.57 |
| | (1.38-1.69) | (0.58-0.87) | (0.49-0.75) | (0.67-0.97) | (0.45-0.69) |
| Potentially preventable dental emergency department presentations | 353 | 72 | 88 | 105 | 90 |
| Rate per 1000 residents (95% CI) | 1.42 | 0.52 | 0.62 | 0.73 | 0.62 |
| | (1.28-1.58) | (0.40-0.64) | (0.43-0.75) | (0.59-0.87) | (0.50-0.75) |
| Dental extractions and restoration | 191 | 47 | 47 | 57 | 43 |
| Rate per 1000 residents (95% CI) | 0.77 | 0.34 | 0.33 | 0.40 | 0.30 |
| | (0.67-0.88) | (0.24-0.44) | (0.23-0.43) | (0.30-0.51) | (0.21-0.39) |
| Oral and dental disorders | 795 | 202 | 189 | 235 | 186 |
| Rate per 1000 residents (95% CI) | 3.19 | 1.45 | 1.34 | 1.66 | 1.29 |
| | (2.98-3.43) | (1.25-1.65) | (1.15-1.53) | (1.44-1.87) | (1.11-1.48) |

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*. Note: The page numbers refer to the submitted manuscript, not to the published article or its supplementary file.

| | Item No | Recommendation | Page No |
|------------------------------|------------|---|-------------------------------------|
| Title and abstract | 1 | (a) Indicate the study's design with a commonly used term in the title or the abstract | |
| | | (b) Provide in the abstract an informative and balanced summary of what was done and what was found | 1 |
| Introduction | | | |
| Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported | 2 |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses | 2 |
| Methods | | | |
| Study design | 4 | Present key elements of study design early in the paper | 2 |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | 2 |
| Participants | 6 | (a) Give the eligibility criteria, and the sources and methods of selection of participants | 2 |
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | 2, Table S1 |
| Data sources/ measurement | 8* | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | 2,Table S1 |
| Bias | 9 | Describe any efforts to address potential sources of bias | N/A |
| Study size | 10 | Explain how the study size was arrived at | N/A |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | 2,Table S1 |
| Statistical methods | 12 | (a) Describe all statistical methods, including those used to control for confounding | 2 |
| | | (b) Describe any methods used to examine subgroups and interactions | N/A |
| | | (c) Explain how missing data were addressed | N/A |
| | | (d) If applicable, describe analytical methods taking account of sampling strategy | N/A |
| | | (e) Describe any sensitivity analyses | N/A |
| Results | | | |
| Participants | 13* | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed | N/A |
| | | (b) Give reasons for non-participation at each stage | N/A |
| | | (c) Consider use of a flow diagram | N/A |
| Descriptive data | 14* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders | 2 |
| | | (b) Indicate number of participants with missing data for each variable of interest | N/A |
| Outcome data | 15* | Report numbers of outcome events or summary measures | 3,Table 1, Table S2, Table S3 |

| Main results | 16 | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included | Table 1, Table S2, Table S3 |
|-------------------|----|--|-----------------------------------|
| | | (b) Report category boundaries when continuous variables were categorized | N/A |
| | | (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | N/A |
| Other analyses | 17 | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses | N/A |
| Discussion | | | |
| Key results | 18 | Summarise key results with reference to study objectives | 3 |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | 3 |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | 3 |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results | 3 |
| Other information | | | |
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | Pending |

^{*}Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.